
    
      A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination
      with Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in
      Subjects with International Federation of Gynecology (FIGO) Stage IVB or Recurrent or
      Persistent Cervical Cancer with Zero or One Prior Chemotherapy Regimen for Advanced/Recurrent
      Disease
    
  